CXCL13 and melanoma: In this study, we revealed that crizotinib, a small‐molecule kinase inhibitor, exhibited superior performance in disrupting this interaction during subsequent immunoprecipitation assays and demonstrated its ability to reduce lactate export, thereby modulating macrophage polarization and impairing CXCL13‐mediated immune escape in melanoma.